Given the above, we hypothesised that RHOA and IDH2 mutations may be suitable markers of MRD in AITL and sought to study their performance as such in comparison to radiological response in patients undergoing treatment. The gene discussed is RHOA; the disease is angioimmunoblastic T-cell lymphoma.